Inhibitor Therapeutics (INTI) Preferred Shares (2013 - 2022)
Inhibitor Therapeutics' (INTI) quarterly Preferred Shares came in at $4.0 million in Q2 2022, little changed on a QoQ basis from $4.0 million in Q4 2021.
Inhibitor Therapeutics (INTI) Preferred Shares (2013 - 2022) Analysis & Trends
Inhibitor Therapeutics (INTI) has 7 years of Preferred Shares data on file, last reported at $4.0 million in Q2 2022.
- Quarterly Preferred Shares changed N/A year-over-year to $4.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $4.0 million (changed N/A YoY) and the FY2021 annual result came in at $4.0 million, changed N/A from the prior year.
- Preferred Shares was little changed at $4.0 million in Q2 2022, from $4.0 million in the prior quarter.
- In the past five years, Preferred Shares ranged from a high of $4.0 million in Q4 2018 to a low of $348.0 in Q1 2018.
- A 5-year average of $3.5 million and a median of $4.0 million in 2018 frame the typical range for Preferred Shares.
- Annual changes were most pronounced in 2019 — Preferred Shares soared 1138079.89% — and 2020, when it changed 0.0%.
- Tracing INTI's Preferred Shares over 5 years: stood at $4.0 million in 2018, then changed by 0.0% to $4.0 million in 2019, then changed by 0.0% to $4.0 million in 2020, then changed by 0.0% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022.
- The last three Preferred Shares figures came in at $4.0 million (Q2 2022), $4.0 million (Q4 2021), and $4.0 million (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 3.96 Mn |
| Dec 31, 2021 | 3.96 Mn |
| Jun 30, 2020 | 3.96 Mn |
| Mar 31, 2020 | 3.96 Mn |
| Sep 30, 2019 | 3.96 Mn |
| Jun 30, 2019 | 3.96 Mn |
| Mar 31, 2019 | 3.96 Mn |
| Dec 31, 2018 | 3.96 Mn |
| Mar 31, 2018 | 348.00 |
| Mar 31, 2014 | 17.00 |
| Dec 31, 2013 | 17.00 |
| Sep 30, 2013 | 17.00 |